Malignant Mesothelioma News
- You are currently viewing this from 69.147.86.151 - Wednesday, November 26, 2008 @ 7:16PMWELCOME GUEST! The roof of the Suva Market is being rapidly changed because it contains toxic asbestos material. Re-elected Suva Lord mayor Ratu Peni Volavola confirmed to Fijilive that the roof contained asbestos and the Suva City Coucil was moving at a rapid pace to get the roof changed.
- Cholesterol Drug Plays Role In Melanoma Remission Wednesday, August 13, 2008 @ 6:17AMA drug widely used to treat high cholesterol is helping beat cancer. Lovastatin is part of a new cancer treatment that has arrested or eradicated tumors in more than 80% of initial patients. The first person treated with the investigative protocol in 2000 had stage 4 melanoma; he remains disease-free today.
- Verdict soon on World Trade Center third tower Friday, July 4, 2008 @ 8:31PMUS experts, investigating the collapse of the third tower at the World Trade Center, say building fires on several different floors probably caused the collapse.
- San Francisco Friday, May 23, 2008 @ 2:05PMChief Y.R. Brewer, 66, of Lyons, Ga., was diagnosed last year with malignant mesothelioma, which affects cells lining the chest cavity. It has been strongly linked to asbestos exposure.
- LegalView Announces the Arrival of a Breakthrough Scientific Study Allowing Insight Into the Development and ... Thursday, May 8, 2008 @ 8:02AMLegalView utilized its mesothelioma blog to report a new mouse model for mesothelioma that reproduces the human disease and provides scientists insights into the way the cancer develops and progresses. The mouse model is for human malignant mesothelioma and will likely lead to breakthroughs in treatments for mesothelioma cancer patients over time. [PR.com - May 07, 2008]
- European Medicines Agency (EMEA) Approves ALIMTA® (pemetrexed For Injection) For Use In Lung Cancer Treatment Monday, April 14, 2008 @ 4:13AMOnApril 11, 2008, an announcement by Eli Lilly and Company (NYSE:LLY) indicated that European health authorities have approved theuse of ALIMTA® (pemetrexed for injection) for a histologically-baseduse in the first-line treatment of advanced non-small-cell lung cancer(NSCLC), the most common form of lung cancer.
- Alfacell signs Onconase distribution agreement with BL&H Wednesday, January 23, 2008 @ 6:09AMAlfacell Corporation has entered into a distribution agreement with BL&H for the commercialization of Onconase in South Korea, Taiwan and Hong Kong. Onconase is currently being evaluated as a treatment for unresectable malignant mesothelioma in a confirmatory Phase IIIb clinical trial.
- Strativa Pharmaceuticals Acquires Commercialization Rights to Onconase(R) from Alfacell Corporation Tuesday, January 15, 2008 @ 8:50AMStrativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX) and Alfacell Corporation (Nasdaq: ACEL) today announced that they have entered into an exclusive licensing agreement under which Strativa has acquired the commercialization rights in the United States and its territories to ONCONASE(R) (ranpirnase) from ...
- Alfacell Corporation Licenses ONCONASE(R) U.S. Commercial Rights to Strativa Pharmaceuticals Tuesday, January 15, 2008 @ 8:50AMAlfacell Corporation (Nasdaq: ACEL) today announced that it has entered into a license agreement with Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), for the commercialization of ONCONASE (ranpirnase) in the United States. ONCONASE is currently being evaluated as a treatment for unresectable malignant ...
- Strativa Pharmaceuticals Acquires Commercialization Rights to Onconase(R) from Alfacell Corporation Tuesday, January 15, 2008 @ 8:30AM Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. and Alfacell Corporation today announced that they have entered into an exclusive licensing agreement under which Strativa has acquired the commercialization rights in the United States and its territories to ONCONASE® from Alfacell.
- Alfacell Corporation Licenses ONCONASE(R) U.S. Commercial Rights to Strativa Pharmaceuticals Tuesday, January 15, 2008 @ 8:30AM Alfacell Corporation today announced that it has entered into a license agreement with Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. , for the commercialization of ONCONASE in the United States.
